G01 : Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, doubleblinded, randomised, placebo-controlled phase II trial

Armstrong, Matthew; Gaunt, Piers; Aithal, Guruprasad P.; Parker, Richard; Barton, Darren; Hull, Diana; Guo, Kathy; Abouda, George; Aldersley, M.; Gough, Stephen; Tomlinson, Jeremy; Brown, Rachel M.; Hübscher, S.G.; Newsome, Philip

doi:10.1016/s0168-8278(15)30002-7

Cited by 17 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whilst the underpinning mechanisms remain to be fully elucidated in humans, the GLP-1 agonist Liraglutide has been shown to be safe and well tolerated in patients with type 2 diabetes and its use is associated with a reduction in ALT [113] . A 12-week intervention with Liraglutide did not improve liver fat on MRS [64] , however, although currently only published in abstract form, Liraglutide has been shown to be an effective treatment for those with NASH both with and without diabetes [114] in a placebo controlled study with improvement in liver biopsy at 52 weeks as the primary outcome. Furthermore, in a study incorporating hyperinsulinaemic–euglycaemic clamps, Liraglutide has been shown to improve hepatic and adipose insulin sensitivity [115] .…”

Section: The Role Of Existing Oral Hypoglycaemic Agentsmentioning

confidence: 92%

Non-alcoholic fatty liver disease and diabetes

et al. 2016

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common conditions that regularly co-exist and can act synergistically to drive adverse outcomes. The presence of both NAFLD and T2DM increases the likelihood of the development of complications of diabetes (including both macro- and micro- vascular complications) as well as augmenting the risk of more severe NAFLD, including cirrhosis, hepatocellular carcinoma and death.The mainstay of NAFLD management is currently to reduce modifiable metabolic risk. Achieving good glycaemic control and optimising weight loss are pivotal to restricting disease progression. Once cirrhosis has developed, it is necessary to screen for complications and minimise the risk of hepatic decompensation.Therapeutic disease modifying options for patients with NAFLD are currently limited. When diabetes and NAFLD co-exist, there are published data that can help inform the clinician as to the most appropriate oral hypoglycaemic agent or injectable therapy that may improve NAFLD, however most of these data are drawn from observations in retrospective series and there is a paucity of well-designed randomised double blind placebo controlled studies with gold-standard end-points. Furthermore, given the heterogeneity of inclusion criteria and primary outcomes, as well as duration of follow-up, it is difficult to draw robust conclusions that are applicable across the entire spectrum of NAFLD and diabetes. In this review, we have summarised and critically evaluated the available data, with the aim of helping to inform the reader as to the most pertinent issues when managing patients with co-existent NAFLD and T2DM.

show abstract

Section: The Role Of Existing Oral Hypoglycaemic Agentsmentioning

confidence: 92%

Non-alcoholic fatty liver disease and diabetes

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Liraglutide is a long-acting GLP-1 agonist that improves key metabolic risk factors: weight, body mass index and glucose level. Besides its metabolic improvement, liraglutide was found to significantly improve liver steatosis in NAFLD patients by downregulating the expression of inflammatory mediators in the TNF-α signaling pathway [53,54]. Additionally, liraglutide affects the renin-angiotensin system (RAS), which is overactivated during NAFLD.…”

Section: Treatment Options Of Nafldmentioning

confidence: 99%

Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review

Głuszyńska

Lemancewicz

Dzięcioł

et al. 2021

JCM

View full text Add to dashboard Cite

The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has considerably increased over the last years. NAFLD is currently the most common cause of chronic liver disease in the developing world. The diagnosis of NAFLD/NASH is often incidental, as the early-stage of disease is frequently free of symptoms. Most patients recognized with NAFLD have severe obesity and other obesity-related disease such as type 2 diabetes mellitus (T2DM), insulin-resistance, dyslipidemia and hypertension. The only proven method for NAFLD improvement and resolution is weight loss. Bariatric surgery leads to significant and long-term weight loss as well as improvement of coexisting diseases. There is a lot of evidence suggesting that metabolic/bariatric surgery is an effective method of NAFLD treatment that leads to reduction in steatosis, hepatic inflammation and fibrosis. However, there is still a need to perform long-term studies in order to determine the role of bariatric surgery as a treatment option for NAFLD and NASH. This review discusses current evidence about epidemiology, pathogenesis and treatment options for NAFLD including bariatric/metabolic surgery and its effect on improvement and resolution of NAFLD.

show abstract

“…[ 46 ] Liraglutide is found to be useful for those with NASH both with diabetes. [ 51 ] In a placebo-controlled study, 39% of patients who received liraglutide had resolution of NASH compared to only 9% in the placebo arm at 52 weeks. [ 51 ] However it is premature to consider GLP1 analogs to specifically treat NAFLD/NASH.…”

Section: G Lucagon -L Ike P mentioning

confidence: 99%

Nonalcoholic fatty liver disease and Type 2 diabetes mellitus

Dharmalingam

Yamasandhi

2018

Indian J Endocr Metab

157

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) commonly exist together. It has been regarded as a manifestation of the metabolic syndrome. The presentations of NAFLD range from simple steatosis (NAFL), nonalcoholic steatohepatitis (NASH), and cirrhosis. NAFLD has a prevalence of 70% among T2DM patients. Overweight/obesity and insulin resistance (IR) have been strongly linked with NAFLD. Noninvasive assessment and staging of disease are based on clinical parameters such as age, sex, liver function test, platelet count, lipid profile, BMI, and imaging modalities such as USG, transient elastography (TE), and magnetic resonance imaging mass spectroscopy. Such clinical scoring systems and TE are useful in the early detection of NAFLD and predicting fibrosis. The principle behind the management of NAFLD with T2DM involves an indirect effect through improvement in IR and glycemia and thus is used for the treatment of T2DM as well.

show abstract

G01 : Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, doubleblinded, randomised, placebo-controlled phase II trial

Cited by 17 publications

References 0 publications

Non-alcoholic fatty liver disease and diabetes

Non-alcoholic fatty liver disease and diabetes

Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review

Nonalcoholic fatty liver disease and Type 2 diabetes mellitus

Contact Info

Product

Resources

About